AI-generated content for informational purposes only. Not financial advice. Always do your own research.

À propos

Xylem Inc. (NYSE: XYL) est une entreprise leader mondiale de technologie de l'eau dédiée à la résolution des défis critiques de l'eau et des infrastructures par le biais de son portefeuille de comptage intelligent, de pompes, de systèmes de traitement et de plateformes d'analyse utilisés par les services publics, les installations industrielles et les bâtiments commerciaux du monde entier. L'acquisition par l'entreprise en 2023 de Evoqua Water Technologies a considérablement élargi ses capacités de traitement de l'eau et ses solutions d'eau industrielle, créant une plateforme de technologie de l'eau complète couvrant le cycle complet de l'eau, de la collecte et la distribution à l'utilisation, le traitement et le retour. La concentration de Xylem sur les solutions numériques de l'eau, les infrastructures intelligentes et le besoin croissant de faire face aux systèmes d'eau vieillissants et à la pénurie d'eau en font un investissement en technologie de l'eau à croissance élevée avec de forts vents de queue structurels.

Actions de l'adaptation au climat

Xylem est un leader mondial des technologies de l'eau dédié à la résolution des défis critiques des infrastructures hydriques, avec des produits pour le traitement, le transport et l'analytique de l'eau essentiels à l'adaptation climatique.

Actions de l'eau

Xylem est une entreprise technologique de l'eau leader fournissant des solutions d'infrastructure intelligente, notamment des pompes, des systèmes de traitement, des analyses et des plates-formes de surveillance numérique qui aident les services publics et les industries à gérer l'eau plus efficacement tout au long du cycle de l'eau.

Key Financials XYL

Prix $128.09
Variation (1J) +1.58%
Variation (30D) -5.94%
Variation (60D) -9.15%
Variation (90D) -14.55%
Variation (180D) +1.94%
Variation (1Y) -1.40%
Variation (5Y) +26.58%
P/E Ratio 25.47
EPS (TTM) $5.03
Plage sur 52 semaines $100.47 — $154.27
MA sur 50 jours $138.47
Volume 2.42M

Data updated Feb 15 · Source: Twelve Data

4.6
2 reviews
Claude Opus 4.6
AI Review
4.6/5

Xylem is a premier pure-play water technology company, offering solutions across water transport, treatment, testing, and smart infrastructure. The 2023 acquisition of Evoqua Water Technologies significantly expanded its treatment capabilities and created meaningful cross-selling opportunities. With a P/E of 25.47 and EPS of $5.03, the stock trades at a premium but one arguably justified by its dominant market position in a secular growth industry. Global water scarcity, aging infrastructure, and tightening regulations provide powerful long-term tailwinds. The recent pullback of ~14.5% over 90 days brings the price closer to fair value territory, currently sitting well below its 50-day moving average of $138.47. Bull case: irreplaceable positioning in essential water infrastructure with recurring revenue streams and margin expansion from Evoqua synergies. Bear case: integration risks, cyclical exposure to municipal spending, and elevated valuation relative to industrial peers. The balance sheet carries acquisition-related debt that warrants monitoring. For investors seeking exposure to water megatrends and climate resilience, Xylem remains a cornerstone holding with strong competitive moats.

Feb 15, 2026
Gemini 3 Pro Preview
AI Review
4.6/5

Xylem Inc. (XYL) stands as a premier pure-play in the water technology sector, offering essential solutions for water transport, treatment, and testing. The company benefits from strong secular tailwinds, including global water scarcity and the urgent need to upgrade aging utility infrastructure. The recent integration of Evoqua Water Technologies has further solidified its competitive moat by expanding its service capabilities. Currently trading at $128.92 with a P/E ratio of 26.64, valuation remains elevated compared to broader industrials but reflects the premium assigned to its market leadership and ESG credentials. The stock has recently pulled back significantly from its 52-week high of $154.27 and is trading below its 50-day moving average, potentially offering a tactical entry point for long-term investors. While cyclical risks in industrial spending persist, Xylem's diverse portfolio provides resilience.

Feb 11, 2026
Xylem Inc Screenshot

Added: Feb 10, 2026

xylem.com

Latest from Otrai

How to Trade Stock Indices: S&P 500, Nasdaq, and Dow via ETFs, Futures, and CFDs

How to Trade Stock Indices: S&P 500, Nasdaq, and Dow via ETFs, Futures, and CFDs

A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.

The Options Greeks Explained: Delta, Gamma, Theta, and Vega

The Options Greeks Explained: Delta, Gamma, Theta, and Vega

The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.

Chart Patterns That Actually Work: Head & Shoulders, Triangles, Flags & Double Tops

Chart Patterns That Actually Work: Head & Shoulders, Triangles, Flags & Double Tops

Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.

Comment tester une stratégie de trading en arrière-plan : méthodes, pièges et ce que les résultats signifient réellement

Comment tester une stratégie de trading en arrière-plan : méthodes, pièges et ce que les résultats signifient réellement

Chaque trader a une stratégie qui semble excellente dans sa tête. Le backtesting est la façon de découvrir si cela fonctionne réellement. Voici comment tester les stratégies correctement, quelles métriques comptent et pourquoi la plupart des résultats de backtesting sont trop beaux pour être vrais.